Adial Pharmaceuticals Faces Delisting Concerns
Ticker: ADIL · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1513525
| Field | Detail |
|---|---|
| Company | Adial Pharmaceuticals, Inc. (ADIL) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: ADIL
TL;DR
ADIL might get delisted, big trouble for shareholders.
AI Summary
Adial Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, to report its notice of delisting or failure to satisfy a continued listing rule or standard. The company is incorporated in Delaware and its fiscal year ends on December 31st. This filing indicates potential issues with maintaining its stock exchange listing.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the company's stock being removed from trading, impacting investors.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to its operations and investors.
Key Players & Entities
- Adial Pharmaceuticals, Inc. (company) — Registrant
- September 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38323 (identifier) — Commission File Number
FAQ
What specific listing rule or standard has Adial Pharmaceuticals, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Adial Pharmaceuticals, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 2, 2025.
In which state is Adial Pharmaceuticals, Inc. incorporated?
Adial Pharmaceuticals, Inc. is incorporated in Delaware.
What is the Commission File Number for Adial Pharmaceuticals, Inc.?
The Commission File Number for Adial Pharmaceuticals, Inc. is 001-38323.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a notice of delisting or failure to satisfy a continued listing rule or standard.
Filing Stats: 998 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2025-09-03 08:48:05
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ADIL The Nasdaq Stock Ma
- $1.00 — maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing
Filing Documents
- ea0255741-8k_adial.htm (8-K) — 30KB
- ea025574101ex99-1_adial.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001213900-25-083719.txt ( ) — 224KB
- adil-20250902.xsd (EX-101.SCH) — 3KB
- adil-20250902_lab.xml (EX-101.LAB) — 33KB
- adil-20250902_pre.xml (EX-101.PRE) — 22KB
- ea0255741-8k_adial_htm.xml (XML) — 4KB
01. Notice of Delisting or Failure to
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 2, 2025, Adial Pharmaceuticals, Inc. (the "Company") received a letter (the "September 2025 Nasdaq Letter") from The Nasdaq Stock Market ("Nasdaq") stating that the Company is eligible for an additional 180 calendar days, or until March 2, 2026, to regain compliance with Nasdaq's requirement to maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on Nasdaq (the "Minimum Bid Price Requirement"), following the expiration of the initial 180 calendar day period granted to the Company by Nasdaq to regain compliance by September 1, 2025 (the "Initial Compliance Date"). Nasdaq initially notified the Company of (i) its failure to meet the Minimum Bid Price Requirement and (ii) the Initial Compliance Date in a letter sent by Nasdaq and addressed to the Company, dated March 5, 2025. The Staff of the Nasdaq (the "Staff") determined that the Company is eligible for the second 180 calendar day period, or until March 2, 2026, to regain compliance with the Rule based on the Staff's determination that the Company must continue to meet the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period, the closing bid price of the Company's common stock on the Nasdaq is at least $1.00 per share for a minimum of ten (10) consecutive business days, the Staff will provide written confirmation of compliance with the Rule and this matter will be closed. The September 2025 Nasdaq Letter from Nasdaq also stated that if the Com
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release, dated September 3, 2025, issued by Adial Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 3, 2025 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer 2